Contact: +91-9711224068
  • Printed Journal
  • Indexed Journal
  • Refereed Journal
  • Peer Reviewed Journal
International Journal of Pharmacy and Pharmaceutical Science

Vol. 6, Issue 1, Part B (2024)

Pulmonary aspergillosis: A COVID-19 associated deadly disease its epidemiology, immunology, diagnosis & treatment

Author(s):

Satbir Singh, Kehar Singh, Hemant Rana and Rahul Kumar

Abstract:
The COVID-19 virus causes lung infections that lead to inflammation and a cytokine storm in the affected person, ultimately impairing their immune system. Tocilizumab and steroids, which are used in the treatment of COVID-19, further reduce an individual's immunity. A secondary or supra-added infection, which could be bacterial or fungal, results from the person's temporary immune compromised state. COVID-associated pulmonary aspergillosis is one such fungal illness. Patients with impaired immune systems, such as those admitted to intensive care units and on mechanical breathing, are more likely to contract this lethal fungus. This review article covers the PULMONARY ASPERGILLOSIS epidemiology, immunology, diagnosis and treatment.

Pages: 105-109  |  49 Views  21 Downloads


International Journal of Pharmacy and Pharmaceutical Science
How to cite this article:
Satbir Singh, Kehar Singh, Hemant Rana and Rahul Kumar. Pulmonary aspergillosis: A COVID-19 associated deadly disease its epidemiology, immunology, diagnosis & treatment. Int. J. Pharm. Pharm. Sci. 2024;6(1):105-109. DOI: 10.33545/26647222.2024.v6.i1b.106
Call for book chapter